Androgen receptor (AR) is commonly expressed in both the epithelium of normal mammary glands and in breast cancers. AR expression in breast cancers is independent of estrogen receptor alpha (ERa) status and is frequently associated with overexpression of the ERBB2 oncogene. AR signaling effects on breast cancer progression may depend on ERa and ERBB2 status. Up to 30% of human breast cancers are driven by overactive ERBB2 signaling and it is not clear whether AR expression affects any steps of tumor progression in this cohort of patients. To test this, we generated mammary specific Ar depleted mice (MARKO) by combining the floxed allele of Ar with the MMTV-cre transgene on an MMTV-NeuNT background and compared them to littermate MMTV-NeuNT, Ar fl /+ control females. Heterozygous MARKO females displayed reduced levels of AR in mammary glands with mosaic AR expression in ductal epithelium. The loss of AR dramatically accelerated the onset of MMTV-NeuNT tumors in female MARKO mice. In this report we show that accelerated MMTV-NeuNT-dependent tumorigenesis is due specifically to the loss of AR, as hormonal levels, estrogen and progesterone receptors expression, and MMTV-NeuNT expression were similar between MARKO and control groups. MMTV-NeuNT induced tumors in both cohorts displayed distinct loss of AR in addition to ERa, PR, and the pioneer factor FOXA1. Erbb3 mRNA levels were significantly elevated in tumors in comparison to normal mammary glands. Thus the loss of AR in mouse mammary epithelium accelerates malignant transformation rather than the rate of tumorigenesis.
Introduction
The majority of breast cancers originate in epithelial cells that line the ducts of the mammary glands. A number of alterations lead to the development of distinct tumor types from these cells. Two of the best described and therapeutically exploited drivers of transformation are estrogen receptor alpha (ERa) and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/ glioblastoma derived oncogene homolog (avian), ERBB2, also known as human epidermal growth factor receptor 2 (HER2/ Neu). However, additional markers are sought that denote molecular signatures that are better able to predict tumor progression, therapeutic response, and probability of recurrence.
According to different reports, 15 to 30% of breast cancers are driven by overexpression of ERBB2 [1, 2] . ERBB2 is part of a complex network comprised of four receptor tyrosine kinases (RTK), ERBB1-4. They can be bound by a variety of peptide hormones which cause receptors to homo-and/or heterodimerize and become active. ERBB2 does not have a ligand and is activated by partnering with itself or other family members [3] . Recent evidence suggests that the most critical partner for ERBB2 driven epithelial transformation and tumorigenesis is ERBB3. In human breast cancer cell lines with amplified ERBB2 expression, depletion of ERBB3 reduces cell proliferation to the same extent as depletion of ERBB2, while loss of ERBB1 (epidermal growth factor receptor (EGFR)) does not affect proliferation [4] . The activated form of ERBB3 was detected in human breast cancers with amplified ERBB2 expression [4] . Multiple mouse models overexpressing ERBB2 in mammary glands have been established, all of which lead to development of mammary tumors [5, 6, 7] . Similar to human breast cancer, ERBB3 plays a central role in murine breast cancer models. Ablation of endogenous Erbb3 in mammary epithelial cells caused a decrease in ERBB2 induced tumor incidence from 93.3% to 6.7% [8] . In contrast, Erbb4 ablation did not affect latency or histological grade of MMTVNeu mouse mammary tumors [9] . As noted in human cancers, elevated expression of activated ERBB3 has been detected in transgenic mice overexpressing activated ERBB2 [10] .
Estrogen, progesterone, and androgen receptors (ERa, PR and AR) are highly expressed in mammary epithelium and are essential for mammary gland development, function, and carcinogenesis. ERa inhibitors, such as tamoxifen, have been a mainstay of cancer prevention trials [11] . Aromatase inhibitors that block conversion of androgens to estrogens have been shown to protect against breast cancer progression in patients positive for ERa and PR [12, 13, 14] . Both ERa and PR are positive prognostic markers in breast cancer and their loss is associated with poor prognosis. Mouse models with either Esr1 or Pr genes knocked out fail to develop functional mammary glands [15, 16] and both receptors are required for mouse mammary tumorigenesis [17, 18] .
AR is expressed in the epithelium of the normal mammary gland and in approximately 70-90% of invasive breast cancers, a frequency comparable to that of ERa (70-80%) or PR (50-70%) [19] . In both normal and malignant human breast tissue there are cells that are positive for AR and ERa and cells that only express AR [20] . The role of AR in breast cancer is currently unclear and seems to depend on the cellular milieu. The expression of AR in ERa positive tumors is associated with less aggressive tumors and a more favorable prognosis [21] . However, AR expression in ERa negative and triple negative tumors is associated with poor prognosis and increased mortality [21] . In ERa negative breast cancer, ERBB2 overexpression significantly correlates with high AR and ERBB3 expression [22, 23, 24] . In MDA-MB-453 breast cancer cells that do not express ERa, AR activates ERBB2 signaling by direct androgen-dependent induction of WNT7B and ERBB3 expression [22] . In mouse models, stimulation of AR signaling mid-puberty suppressed epithelial proliferation and development of ductal extensions [25] . Global AR knockout significantly increased the susceptibility of the mammary gland to the chemical carcinogen, DMBA, presumably by elevating estrogenic activity [26] .
Since AR is frequently expressed in ERBB2 amplified tumors, we asked how the loss of AR signaling would affect tumor incidence and progression in this cohort. We described here analysis of breast tumorigenesis in mice with overexpression of an activated form of ERBB2 and conditional deletion of the Ar allele specifically in the mammary gland epithelium (MARKO). Remarkably, the first tumors in female MARKO mice were detected almost 100 days earlier than in control mice. Similar to human ERBB2 driven breast cancer, tumors in ERBB2 transgenic animals show simultaneous increase in endogenous ERBB3 but not ERBB4 expression [8, 22, 27, 28] . We observed that tumors in both control and MARKO mice showed reduced gene expression of the steroid receptors Era, Pr, Ar and their pioneer factor Foxa1. Our data suggest that ERBB2/ERBB3 driven tumorigenesis is opposed by AR and its loss results in earlier tumor development.
Methods

Animal Breeding and Genotyping
Animal studies were conducted in accordance with the humane standards of animal care, as outlined in the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and all procedures were approved by the Florida International University Institutional Animal Care and Use Committee. All mice were maintained in a temperature controlled room, with 12-h light, 12-h dark photocycle and fed Teklad global 18% protein rodent diet chow (Harlan, Indianapolis, IN) and fresh water ad libitum. Transgenic mice (FVB-Tg(MMTV-ErbB2)NK1Mul/J) containing the activated rat ERBB2 oncogene targeted to the mammary epithelium by the MMTV-LTR promoter (hereafter referred to as MMTV-NeuNT) [7] and mice with the Cre recombinase transgene under the control of the MMTV-LTR promoter (Tg(MMTV-cre)1Mam/J, MMTV-cre) [29] were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice with floxed exon 2 of the X chromosomal androgen receptor gene (Ar fl ) were described previously [30] . Deletion of Exon 2 causes a frame shift and production of an unstable amino-terminal fragment, completely lacking the DNA binding domain. Transgenic mice were genotyped by PCR from genomic DNA isolated by ear punches with primers specific to the ERBB2 and cre transgenes and wild-type, floxed and deleted (Ar 
Incidence and Survival Study
MARKO females (n = 19) and males (n = 33) and littermate controls (females, n = 29; males, n = 31) were used in the survival study. All females were kept as virgins for the entire period of study. Mice were palpated at least twice a week to detect tumors. Tumor bearing mice were kept until they met euthanasia criteria which included tumor burden of 10% of the body weight or more, significant loss of weight, visible signs of distress, huddled posture, immobility, moribund appearance. The age of mice when a tumor was first detected (incidence) and the age of mice when euthanized due to tumor burden (survival) were recorded. At the time of euthanasia serum was collected, tumors and mammary glands were removed for histological analysis, RNA and DNA isolated, and other organs were examined for metastases. All female mice were sacrificed at 400 days of age and at 450 days for males. Kaplan-Meier survival plots were generated and compared by Log-rank test statistical analyses using GraphPad Prism software (GraphPad Software, San Diego, CA). P,0.05 was considered statistically significant.
Histology and Immunohistochemistry
Mammary glands and tumors were fixed in 4% paraformaldehyde at 4uC overnight. Deparaffinized 5 mm sections of both tumors and normal mammary glands were immunostained for ERa, AR, ERBB2, and Ki67. All washes were done in TBS with 0.05% Tween-20. Antigen retrieval for ERBB2 was achieved by boiling for one minute, followed by fifteen minutes at 90uC in 1 mM EDTA pH 8.0. ERa and AR antigen retrieval was done by heating to 99uC in pH 6.0 10 mM sodium citrate buffer for fifteen minutes, with the addition of 1 mM EDTA for AR. Endogenous peroxidase activity was blocked using 1% H 2 O 2 in methanol for ten minutes. Endogenous biotin was blocked using the Avidin/ Biotin Blocking Kit (Vector Laboratories, Burlingame, CA), followed by blocking with 10% normal goat serum in TBS for 45 minutes. Immunostaining for AR (RB-1358, 1:50, Neomarkers, Fremont, CA), ERa (SC-542, 1:250, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and ERBB2 (mAB#4290, 1:100, Cell Signaling Technology, Danvers, MA) were performed overnight at 4uC diluted in 3% BSA in TBS. Ki67 sections were incubated in primary antibody (RB-1510-P1, 1:100, Neomarkers) in TBS for one hour at room temperature. AR, ERa, and ERBB2 stained sections were incubated with biotinylated goat anti-rabbit secondary antibody for 30 min at room temperature and then with streptavidin conjugated peroxidase for 30 min at room temperature. Ki67 was labeled using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Staining was developed for all proteins using the ImmPACT DAB Peroxidase Substrate Kit (Vector Laboratories) and all slides were counterstained with haematoxylin. 
Tissue Preparation and Gene Expression Analysis
Largest cellular compartment of the mouse mammary gland is fat. To remove fat cells, excised mammary glands were incubated in 1% w/v collagenase (Roche, Mannheim, Germany) dissolved in Earle's Balanced Salt Solution at 37uC with constant agitation for 1 hour. Dissociated tissue was centrifuged at 1000 rpm for 5 min and upper layer of fat cells and overlaying buffer removed. An aliquot of pelleted cells was taken for DNA extraction using DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) and the remaining cells were resuspended in TRIzol reagent (Life Technologies, Grand Island, NY). RNA was extracted according to the manufacturer's instructions. Five micrograms of total RNA was reverse transcribed to cDNA using the GoScript cDNA synthesis kit (Promega, Madison, WI). Quantitative PCR analysis of gene expression was performed using Roche Universal ProbeLibrary assays on a Roche 480 LightCycler. For a complete list of primers see Table S1 .
Hormone Analysis
Mice were anesthetized by isoflurane inhalation (Webster Veterinary, Devens, MA), and blood collected by ocular orbital bleeding. Serum was isolated by centrifugation and stored at20uC until analysis. Testosterone and estradiol measurements were performed by radioimmunoassay (RIA) and ELISA (Calbiotech, San Diego, CA) respectively in the University of Virginia Center for Research in Reproduction Ligand Assay and Analysis Core (University of Virginia, Charlottesville). Sensitivity of the testosterone RIA assay was 10 ng/dL. Sensitivity of the estradiol ELISA assay was 7 pg/ml.
Statistical Analysis
Student t-test for two groups and one-way ANOVA for multiple group comparisons were used to assess significance of differences. Differences were expressed as mean 6SEM; P,0.05 was considered significant. Tumor incidence data was analyzed using Gehan-Breslow-Wilcoxon test. All analyses were performed using the GraphPad Software package.
Results
Female MARKO Mice Display a Mosaic Pattern of AR Expression in the Mammary Gland
To assess the role of the AR in ERBB2 driven tumorigenesis, we crossed MMTV-cre, MMTV-NeuNT mice with Global knockout of Ar in female mice was previously shown to increase luminal epithelial cell proliferation [26] . In our conditional knockout model, we observed similar luminal epithelial cell proliferation in female MARKO and control mice (Figure 2 ).
Diminished AR Expression Promotes an Early Onset of ERBB2 Tumors
The first tumors in MARKO mice were observed almost 100 days prior to the appearance of palpable tumors in control mice ( Figure 3A) . AR deficiency in the mammary glands of female mice dramatically accelerated the onset of MMTV-NeuNT driven tumors. In female mice that developed tumors within 400 days, MARKO mice had a significantly lower average age of tumor onset (273618.36 days) compared to their control littermates (352.568.263 days, P = 0.0005) ( Figure 3B ). To evaluate whether loss of AR affected survival, females were sacrificed when tumors grew to approximately 1.5 cm in diameter, an animal had multiple tumors, or showed signs of morbidity, and the survival curves were calculated. The similar average size of tumors in the two groups (Control = 1.9160.27 g and MARKO = 1.7160.47 g) demonstrated that the mice were sacrificed without preferential selection. Concordantly with an earlier onset of tumors, the survival rate in MARKO females within the first 375 days was significantly reduced (P = 0.0208, Log-rank Test). However, no significant difference was observed in the survival rate between control and MARKO mice during the full course of this study (400 days) ( Figure 3C , P = 0.2376). Similar numbers of females in both groups (36.84% (7/19) in MARKO versus 27.58% (8/29) in Control) developed lethal cancer within the period of the study. The time between tumor detection and euthanasia between two groups was slightly lower in the Control group, however the difference was not statistically significant ( Figure 3D ). At 400 days, 2 female control mice were determined to have small mammary tumors, while no MARKO mice had detectable tumors. Therefore at the completion of the study, 58.6% (17/29) of control mice and 63.16% (12/19) of MARKO females were tumor free. Similar numbers of tumor-bearing mice in the two groups had multiple tumors (41.6%, 5/12 in Control and 43.8%, 3/7 in MARKO). Although MARKO females displayed an earlier onset of MMTVNeuNT tumors, the cell proliferation index evaluated by Ki67 staining in tumors isolated at sacrifice was similar in both groups (Fig. S1 ). Histological analysis of tumors showed that tumors were poorly differentiated and had a uniform morphology comprised of compact adenocarcinoma cells, characteristic for this model [7] with limited portions of intratumoral stroma ( Figure 3E and F) . Histological grading of the tumors was similar between both groups (Table 1) . No metastases were detected in our experiments.
Previously it was shown that MMTV-NeuNT caused the development of mammary tumors in male mice [7] . In our study only 10.9% of males developed tumors within 450 days, including 2/33 in the MARKO group (,6%) and 5/31 in the control group (,16%), and of these mice only 3 were sacrificed due to tumor burden. PCR analysis showed the presence of deleted Ar D allele in all samples of genomic DNA isolated from MARKO male mammary glands ( Figure 1B) . The low number of tumor-bearing mice during the course of this study prevented further evaluation of the role of AR deletion in MMTV-NeuNT male mice.
AR does not Suppress Mammary Gland Mitogenic Signaling Pathways
To determine if AR loss influenced hormone status in our model we evaluated the serum concentrations of estradiol and testosterone. No changes in serum estradiol or testosterone levels were detected between control and MARKO mice ( Figure 4A and 4B). Expression of Esr1, Pr and downstream target genes of both receptors: amphiregulin (Areg), receptor activator of nuclear factor kappa-B ligand (Rankl), and wingless-type MMTV integration site family, member 4 (Wnt4) were also unchanged in non-tumor bearing mammary glands of MARKO mice compared to controls (Fig. S2) .
In both MARKO and control mice, Errb2 transgene expression was dramatically increased in tumors compared to normal nontumor bearing mammary glands from the same animals ( Figure 4C ). Elevated Erbb2 expression was similar in both MARKO and control tumors (p = 0.2197). Increased ERBB2 protein levels were detected in tumors ( Figure 4D and 4E compared to 4F and 4G), corresponding to the elevated mRNA levels.
Overexpression of ERBB2 in human patients is associated with elevated expression or activity of ERBB3 [22] . Elevated levels of ERBB3 protein have been noted in tumors of ERBB2 transgenic mice [10] . We compared the expression of Erbb3 in tumors from control and MARKO mice to non-tumor bearing mammary glands. Strikingly, increased expression of ERBB2 was associated with 18 to 20 fold increased expression of endogenous Erbb3 ( Figure 4H ). Loss of Ar in MARKO mice did not alter increased Erbb3 expression. To evaluate whether Erbb3 upregulation in MMTV-NeuNT tumors was selective or whether these tumors displayed elevated expression of other ERBB family members, we also examined the expression of Erbb4. Expression of Erbb4 in both normal cohorts was similar and was significantly reduced in tumors ( Figure 4I ) (normal versus tumor in Control p = 0.0310 and MARKO p = 0.0272). No significant difference was noted between tumors from the two groups. This suggests that Erbb3 is selectively upregulated to cooperate with ERBB2 driven tumorigenesis.
ERa and PR Signaling is Maintained during AR Loss in Ductal Epithelium
Hormonal independence of breast cancer can occur with disease progression and induction of ERBB2 signaling [33, 34] . Therefore we evaluated the expression of sex steroid receptors in tumors obtained from control and MARKO mice and compared them to each other and to non-tumor bearing mammary glands. Ar expression was significantly reduced in MARKO tumors compared to tumors from control mice ( Figure 5A ). In addition, regardless of genotype, we observed significant loss of Ar expression in MMTV-NeuNT tumors compared to normal mammary glands ( Figure 5A ).
Similarly to Ar, Esr1 and Pr expression was significantly reduced in MMTV-NeuNT tumors compared to non-tumor bearing mammary glands ( Figure 5B and C) . We observed similar Esr1 To confirm reduced steroid receptor signaling in MMTVNeuNT tumors, the expression of known ERa and PR target genes (Areg, RankL and Wnt4) were examined. As was observed for the receptors, expression of these target genes was significantly reduced in MMTV-NeuNT tumors compared to normal mammary glands (Figure 6 ). Expression of RankL was elevated in normal mammary glands of MARKO mice compared to Controls, although it failed to reach statistical significance (p = 0.3036). Pr is an ERa target gene and therefore the reduced expression of Pr and downstream genes may be the consequence of reduced ERa expression. This data further confirms that steroid receptor signaling is reduced in MMTV-NeuNT tumors. No significant difference in expression of Areg, RankL, or Wnt4 was detected between the tumors of control and MARKO mice ( Figure 6 ). This was consistent with similar levels of Esr1 and Pr expression in tumors.
Since the steroid receptors themselves were diminished in MMTV-NeuNT tumors, we examined the status of FOXA1, a pioneer factor closely associated with ERa and AR function [35, 36] and with ERBB2 expression [37, 38] . Interestingly, we observed a significant loss of Foxa1 expression in tumors ( Figure 6D ).
MMTV-NeuNT Expression does not Affect Steroid Receptor Status Prior to Tumor Formation
Loss of steroid receptor and Foxa1 expression in MMTVNeuNT tumors indicated that Erbb2 expression drove the loss of these markers and that their loss may be associated with tumor etiology. To evaluate whether Erbb2 altered the expression of these genes prior to tumor formation, we compared their expression in normal mammary glands from MMTV-NeuNT expressing mice and nontransgenic mice with the same mixed genetic background (minus MMTV-NeuNT). Expression of the rat Erbb2 transgene was detected only in MMTV-NeuNT mice ( Figure 7A ). No significant change in Ar, Esr1, or Pr expression was observed ( Figure 7B, 7C, and 7D ). Foxa1 showed no change in expression between MMTV-NeuNT expressing and non-expressing mammary glands ( Figure 7E ).
Discussion
To investigate the role of AR in ERBB2 driven tumorigenesis we created a mouse model that expressed an activated mutant of rat ERBB2 [7] and were heterozygous for Ar deletion. Due to X chromosomal inactivation in females the floxed or wild type Ar allele may be inactivated. In luminal epithelial cells of MARKO mice where the floxed allele is inactivated, Cre recombinase will fail to ablate AR and therefore these mice will retain a portion of cells with normal AR expression. This was reflected in AR expression analysis of MARKO mammary glands, which displayed an approximately 30% decrease in Ar at the mRNA level. We utilized only partial dissociation of the mammary gland to evaluate gene expression. Therefore, the presence of stromal cells, vasculature, and some fat cells likely reduced the true extent of Ar deletion. Possible proliferative advantage of one genotype over the other and penetrance of MMTV-cre expression may also contribute to varied recombination frequency. AR histological staining confirmed that MARKO mice display a significant reduction in the number of luminal epithelial cells positive for AR.
The current model does not generate complete ablation of Ar across the entire mammary gland; rather it creates a mixed population of epithelial cells expressing normal levels of AR and cells with complete lack of expression. Genetic alterations that give rise to breast cancer or promote tumor progression are thought to In the current study, we noticed a considerable delay in the onset of tumors in control mice (MMTV-NeuNT, Ar fl /+) compared with the incidence reported for the original parent colony ((FVB-Tg(MMTV-ErbB2)NK1Mul/J), which reported 50% incidence in female mice by 25 weeks of age [7] . This disparity is possibly due to differences in the genetic background of mouse strains; the original line is on an FVB background, whereas Ar fl/fl mice are on a C57BL/6 background. C57BL/6 mice are reported to be more resistant to multiple types of tumors [39, 40, 41] . Furthermore, we observed almost no tumor development in our male cohort of mice over a period of 65 weeks. We were interested to determine if AR deletion also affected the susceptibility of male breast cancers, since men with partial or complete androgen insensitivity (AIS) have an elevated risk of breast cancer. AIS associated breast cancer risk is typically associated with elevated estrogen exposure [42] . The lack of tumor development in male mice was also probably due to the mixed background utilized in the current study.
It has previously been reported that global AR knockout increases the susceptibility of female mice to DMBA-induced mammary tumors [26] . Increased tumor susceptibility in ARKO females was associated with elevated proliferation of luminal epithelial cells in virgin mice. Increased proliferation in ARKO females was likely due to the loss of AR antagonism of ERa signaling. In the ARKO study, mammary glands were selectively collected at 8 weeks of age during the estrus phase of the estrous cycle, at which time estrogens exert their largest influence. In the present study, normal mammary glands were collected either at sacrifice due to tumor burden or once females reached 400 days of age independently of the estrous cycle. While we did not observe significant change in proliferation rates, the possibility that MARKO mice have elevated proliferation in the AR depleted luminal epithelium during estrus cannot be excluded.
Inhibition of AR signaling by the antagonist flutamide in postpubertal mice significantly increased proliferation of mammary epithelial cells [25] , indicating that the blockade of AR signaling disrupts the homeostatic balance between estrogen and androgen signaling thus leading to unconstrained estrogen driven proliferation. As seen in the current study, suppression of AR function did not influence estradiol levels or ERa expression. Thus, it is the loss of AR signaling in the normal mammary gland under the influence of normal hormone levels and female steroid receptor status that increases the susceptibility of the mammary gland to further tumor-initiating insults.
Elevated estrogen exposure is a risk factor for breast cancer development and continuous exposure to estrogen in rodents is sufficient to drive the formation of mammary tumors [43] . ERa knockout (ERKO) inhibits the development of mammary tumors in mice [18, 44] . In the MMTV-NeuNT mouse model both ERa and NeuNT are required for tumorigenesis as ERKO mice display significant delay in the development of MMTV-NeuNT tumors. The AR antagonizes the mitogenic activity of the estrogen receptor [45] suggesting that AR may oppose ERa activity during the early stages of MMTV-NeuNT driven tumorigenesis and AR loss leads to the accelerated onset of mammary tumors.
Distinct from human breast cancers, which frequently retain steroid receptors, mouse models of breast cancer frequently lack steroid receptors and develop hormone independence [46, 47, 48] . In the present study we demonstrate that in the MMTV-NeuNT mouse model of breast cancer the expression of AR in these tumors is reduced. This suggests that although the AR suppresses the formation of ERBB2 driven tumors, once these tumors are established they may become less reliant or responsive to androgens or ovarian hormones.
The function of ERa and AR are dependent on the pioneer factor FOXA1 and mammary glands fail to develop in FOXA1 knockout animals [49, 50] . Although the precise significance of FOXA1 expression in breast cancer is unclear, FOXA1 expression has been shown as a positive prognostic factor in ERa positive tumors. A strong correlation between FOXA1 overexpression and ERBB2 in ERa negative tumors has also been identified [51, 52] . There are reports of crosstalk between FOXA1, AR and ERBB2 [52, 53] and of mutual regulation of expression by FOXA1 and ERa [49] . In the present study we demonstrate that MMTVNeuNT tumors have reduced expression of Foxa1 relative to nontumor bearing mammary glands. It would be interesting to determine if loss of FOXA1 drives the development of hormone independent tumors through perturbed steroid receptor signaling or if Foxa1 expression is diminished due to the reduced expression of ERa and/or AR.
ERBB3 overexpression and activation has been detected in tumors from several lines of ERBB2 transgenic mice [10] . However, unlike the previous report that detected minimal elevation in Erbb3 transcription, we note a significant up regulation of Erbb3 mRNA in MMTV-NeuNT tumors. This indicates that in different mouse models of ERBB2 oncogenic activation endogenous ERBB3 is selectively upregulated, although by different mechanisms. Although mutated ERBB2 is capable of homodimerizing, ERBB2/ERBB3 heterodimers can utilize mouse growth hormone signaling and may be required for tumorigenesis. We also observed no increase in Erbb4 expression. This suggests that NeuNT transformation selectively amplifies Erbb3 expression to drive tumorigenesis. Diminished expression of AR in the mammary glands of female mice leads to dramatically earlier onset of MMTV-NeuNT induced mammary tumors. Interestingly, AR loss did not result in an increase in the percentage of tumor-bearing mice in the MARKO group compared to controls. Female ARKO mice do not develop mammary tumors [26] and, in our study, neither do female MARKO mice that do not have the MMTV-NeuNT transgene. Thus, AR inactivation alone does not predispose the mammary gland to mammary tumors. This indicates that the AR opposes mammary gland transformation and its loss predisposes mammary epithelial cells to malignant growth instigated by other oncogenes.
MARKO tumors display the same profile as control tumors; proliferation rate, tumor growth rate, steroid receptor and downstream signaling profiles. In addition, Foxa1 and Erbb3/ Erbb4 expression levels are similar. Therefore it is the loss of AR function that makes it easier for epithelial cells expressing ERBB2 to undergo malignant transformation. 
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